Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 8/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 8/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | FERMT2 | Q96AC1 | 3/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13993581 | 0.86 | PDE5A (0.44) | HTR1AADRA1DADRA1AADRA1BCCR1 | |
| SCHEMBL243582 | 0.86 | FERMT2 (0.61) | HTR1AADRA1DADRA1AADRA1BCCR1 | |
| SCHEMBL3783903 | 0.85 | HTR1A (0.40) | HTR1AADRA1DADRA1AADRA1BCCR1 | |
| SCHEMBL241335 | 0.84 | HTR1A (0.44) | HTR1AADRA1DADRA1AADRA1BCCR1 | |
| SCHEMBL241000 | 0.84 | KDM4E (0.61) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL241983 | 0.83 | FERMT2 (0.51) | HTR1AADRA1DADRA1AADRA1BCCR1 | |
| SCHEMBL242051 | 0.79 | MEN1 (0.55) | — | |
| SCHEMBL4988313 | 0.79 | CLK1 (0.36) | CYP1A2 | |
| SCHEMBL242703 | 0.79 | HRH3 (0.60) | — | |
| SCHEMBL238033 | 0.78 | HTR1A (0.41) | HTR1AADRA1DADRA1AADRA1BCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468366-B2 | Cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1453812-B1 | CYTOTOXIC AGENTS | UNIV RUTGERS (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080090831-A1 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-04-17 | — | — | US | disclosed |
| US-7319105-B2 | Methylenedioxy-fused heterocycles, especially 8,10-dioxa-4,5,6,12-tetraaza-cyclopenta[b]chrysen-13-ones; 8,10-dioxa-1,4,5,6,12-pentaaza-cyclopenta[b]chrysen-13-ones; 8,10,12-trioxa-5,6-diaza-cyclopenta[b]chrysenes; and 8,10,12-trioxa-6-aza-cyclopenta[b]chrysenes; topoisomerase inhibitors; treating cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050009825-A1 | Cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2005-01-13 | — | — | US | disclosed |
| EP-1453812-A2 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003041653-A2 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009825-A1 | Cytotoxic agents | TOP1, TOP2A, TOP2B | HTR1A 3945/4885ADRA1D 4405/4885ADRA1A 4113/4885 |
| US-20080090831-A1 | CYTOTOXIC AGENTS | TOP1, TOP2A, TOP2B | HTR1A 3945/4885ADRA1D 4405/4885ADRA1A 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.